The Trump administration’s 2025 drug policy agenda omits cannabis rescheduling, despite earlier signals of support, instead prioritizing fentanyl, border security, and addiction treatment. This omission, coupled with a...more
6/9/2025
/ Biden Administration ,
Cannabis Products ,
DEA ,
Department of Justice (DOJ) ,
Legislative Agendas ,
Marijuana ,
New Legislation ,
Opioid ,
Proposed Legislation ,
Regulatory Reform ,
Trump Administration
If the Federal Government reschedules marijuana, experts believe it could lead to a cascade of state-level changes.
There is growing evidence that Joe Biden’s administration is working on moving marijuana to Schedule III...more
There Has Been Little Movement in Federal Legalization. This has led to cannabis investors and companies to downgrade expectations for federal legalization and focus their strategies on state reform.
Federal lawmakers...more
7/27/2023
/ Banking Sector ,
Banks ,
Biden Administration ,
Cannabidiol (CBD) oil ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Cole Memorandum ,
Congressional Investigations & Hearings ,
DEA ,
Decriminalization of Marijuana ,
Department of Justice (DOJ) ,
Hemp ,
Hemp Related Businesses ,
Information Reports ,
Interstate Commerce ,
Marijuana ,
Marijuana Cultivation ,
Marijuana Related Businesses ,
Medical Marijuana ,
Proposed Legislation ,
Regulatory Agenda ,
State and Local Government ,
Tax Revenues ,
THC